Chemo-Immunotherapy, gemcitabine with pegylated interferon alpha-2b (Peg-Intron) with and without p53 synthetic long peptide (p53 SLP) vaccine, for patients with platinum resistant ovarian cancer. CHIP trial

Trial Profile

Chemo-Immunotherapy, gemcitabine with pegylated interferon alpha-2b (Peg-Intron) with and without p53 synthetic long peptide (p53 SLP) vaccine, for patients with platinum resistant ovarian cancer. CHIP trial

Completed
Phase of Trial: Phase I/II

Latest Information Update: 13 Oct 2016

At a glance

  • Drugs ISA 102 (Primary) ; Gemcitabine; Peginterferon alfa-2b
  • Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
  • Focus Therapeutic Use
  • Acronyms CHIP
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 16 Jul 2012 New source identified and integrated (ClinicalTrials.gov record NCT01639885).
    • 25 Jun 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top